Wei Guo

Wei Guo

Auto-generated profile, based on publicly available information

Wei Guo

Department of Hematology the First Hospital of Jilin University Changchun China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
HYHaiyan Yang
Haiyan Yang
BXBing Xiang
Bing Xiang
YSYuqin Song
Yuqin Song
HZHuilai Zhang
Huilai Zhang
WZWeili Zhao
Weili Zhao
YLYu-Fu Li
Yu-Fu Li
The non-germinal center B-cell like (non-GCB) subtype of diffuse large B-cell lymphoma (DLBCL) has poor clinical outcomes. Bruton tyrosine kinase (BTK) inhibitors have established therapeutic activity in B-cell malignancies, with modest activity in DLBCL. Zanubrutinib, a potent and selective BTK inhibitor, was evaluated in patients with relapsed or refractory (R/R) non-GCB DLBCL. The BGB-3111-207 study (NCT03145064) was a multicenter single-arm phase 2 study. Patients received twice-daily oral zanubrutinib, 160 mg, until disease progression or unacceptable toxicity. The primary end point was the overall response rate (ORR). Secondary end points included progression-free survival (PFS) and duration of response (DOR). Overall survival (OS) was an exploratory end point. Forty-one patients were enrolled in China after having progressed or not responded to prior therapy. At data cutoff, 4 patients continued treatment with 37 discontinuations. The median follow-up was 6.8 months, the ORR was 29.3%, and the complete response rate was 17.1%. Median DOR, PFS, and OS were 4.5, 2.8, and 8.4 months, respectively. Adverse events (AEs) leading to treatment discontinuation were reported in 4 patients, and grade ≥ 3 AEs were reported in 48.8% of patients. Major hemorrhage, atrial fibrillation, and/or flutter were not observed. Zanubrutinib demonstrated modest antitumor activity in non-GCB DLBCL, like other BTK inhibitors, as well as a safety profile consistent with previous studies. Through retrospective biomarker testing, potential antitumor activity was observed in patients with both CD79B and MYD88 mutations, who have inferior outcomes to immunochemotherapy. Future studies of zanubrutinib in R/R non-GCB DLBCL will focus on developing mechanism-based treatment combinations and biomarker-driven patient selection.

1 March 2019 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
Erica LocatelliErica Locatelli
Erica Locatelli
YLYan Li
Yan Li
IMIlaria Monaco
Ilaria Monaco
WGWei Guo
Wei Guo
Mirko MaturiMirko Maturi
Mirko Maturi
Mauro Comes-FranchiniMauro Comes-Franchini
Mauro Comes-Franchini
Introduction and purpose: Cancer stem cells (CSCs) present a higher capacity to evade being killed by cancer agents and developing chemoresistance, thus leading to failure of conventional anticancer therapeutics. Nanomaterials specifically designed for targeting and treating not only tumor cells, but also CSCs, may encompass therapeutic and diagnostic tools, thus successfully eradicating the tumor. Materials and methods: Polymeric micelles simultaneously loaded with gold nanorods (GNRs) and Adriamycin were prepared and used as a novel therapeutic and diagnostic weapon. Epithelial cell adhesion molecule (EpCAM) is an important CSC surface marker and has been exploited in this work as an active targeting agent. Photoacoustic imaging was applied for GNR individuation and tissue recognition. Results: The nanosystem was demonstrated to be able to elicit effective targeting of cancer cells and cause their killing, in particular under laser ablation. Moreover, ex vivo photoacoustic imaging is able to clearly identify tumor regions thanks to GNR’s contrast. Conclusion: The nanosystem can be considered a powerful and promising theranostic weapon for hepatocellular carcinoma treatment.

25 October 2024 in Science Advances
Verified
Journal Article
Open access
XSXiaoju Shi
Xiaoju Shi
QZQianqian Zheng
Qianqian Zheng
XWXingtong Wang
Xingtong Wang
WGWei Guo
Wei Guo
ZLZiqi Lin
Ziqi Lin
YLYan Li
Yan Li
Metabolic dysfunction–associated steatohepatitis is well accepted as a potential precursor of hepatocellular carcinoma. Previously, we reported that fibroblast growth factor 21 (FGF21) revealed a novel anti-inflammatory activity via inhibiting the TLR4–IL-17A signaling, which could be a potential anticarcinogenetic mechanism to prevent to MASH-HCC transition. Here, we set out to determine whether FGF21 has a major impact on Kupffer cells’ (KCs) ability during MASH-HCC transition. We found aberrant hepatic FGF21 and KC pool in human MASH-HCC. Lack of FGF21 up-regulated ALOX15, which converted the oxidized fatty acids to induce excessive KC death and mobilization of monocyte-derived macrophages (MoMFs) for KC replacement. Lack of FGF21 oversupplied free fatty acids for sphingosine-1-phosphate (S1P) cascade synthesis to mediate MASH-HCC transition via S1P-YAP signaling and cross-talk between tumor cells and macrophages. In conclusion, lack of FGF21 accelerated MASH-HCC transition via the S1P-AP signaling. Compromised MoMFs could present as tumor-associated macrophage phenotype rendering tumor immune microenvironment for MASH-HCC transition.

13 April 2020 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
XHXinxing Huang
Xinxing Huang
KYKen H. Young
Ken H. Young
WGWei Guo
Wei Guo
YWYinping Wang
Yinping Wang
XWXueju Wang
Xueju Wang
OBou bai
ou bai

3 May 2023 in Discover Oncology
Verified
Journal Article
Open access
PDF file
ZZZhumei Zhan
Zhumei Zhan
WGWei Guo
Wei Guo
JLJia Li
Jia Li
XWXin Wan
Xin Wan
JGJing Guo
Jing Guo
OBou bai
ou bai
To investigate the clinical features, survival, and prognostic factors of patients with double primary malignant neoplasms (DPMNs) comprising non-Hodgkin lymphoma (NHL) and malignant solid tumors. Of the 2352 patients diagnosed with NHL, 105 (4.46%) patients were diagnosed with DPMNs, 42 (40.0%) had NHL first (the NHL-first group) and 63 (60.0%) had solid tumor first (the ST-first group). Females were more frequent in the ST-first group, and the interval time between the two tumors was longer. More NHLs in early stages and originating from extranodal sites were observed in the NHL-first group. Male, age ≥ 55 years at diagnosis of the first tumor, interval time <60 months, NHL diagnosed first, NHL arising from an extranodal site, DPMNs without breast cancer, and no surgery for the first primary tumor were associated with poorer overall survival (OS). Interval time <60 months and NHL diagnosed first were independent risk factors that affected the prognosis of patients with DPMNs. Therefore, careful monitoring and follow-up are especially important for these patients. 50.5% (53/105) of patients with DPMNs did not receive chemotherapy or radiotherapy prior to the diagnosis of the second tumor. We further compared the baseline characteristics of diffuse large B-cell lymphoma(DLBCL) patients with and without solid tumors, the former had a higher proportion of extranodal DLBCL, suggesting that extranodal DLBCL is more likely to develop solid tumors than nodal DLBCL.

11 August 2026 in Blood Cancer Discovery
Verified
Journal Article
Closed access
RXRuixian Xing
Ruixian Xing
AYApeng Yang
Apeng Yang
JHjuan huang
juan huang
LWLiang Wang
Liang Wang
WGWei Guo
Wei Guo
LFLin Fu
Lin Fu
Relapsed or refractory central nervous system lymphoma (R/R CNSL) has limited treatment options. This multicenter retrospective study enrolled 84 consecutive patients with R/R CNSL [median age, 59 years; median of 2.5 prior lines of therapy; 53 primary CNSL (PCNSL) and 31 secondary CNSL (SCNSL)] to evaluate the efficacy and safety profiles of glofitamab therapy. For PCNSL, the objective response rate (ORR) was 88% and complete response rate (CRR) was 59% with glofitamab monotherapy (n = 32) and 100% and 81% with combination therapy (n = 21), respectively. For SCNSL, ORR and CRR were 88% and 75% with glofitamab monotherapy (n = 8) and 91% and 65% with combination therapy (n = 23). At 14.7 months of follow-up, median progression-free survival was 19.5 months for PCNSL and 13.5 months for SCNSL. Cytokine release syndrome occurred in 40% (all grades 1–2) of patients, and immune effector cell–associated neurotoxicity syndrome occurred in 8%. Glofitamab-based therapy demonstrated substantial activity with manageable toxicity in this study, offering a promising treatment paradigm for patients with R/R CNSL. Significance: Effective therapies are urgently needed for R/R CNSL. Glofitamab-based therapy demonstrated high response rates in PCNSL (ORR, 92%; CRR, 68%) and SCNSL (ORR, 90%; CRR, 68%) with manageable toxicity in 84 consecutive, heavily pretreated patients, establishing a promising treatment option for this high-risk population.